Abstract
We compared the efficacy of ganciclovir versus that of cytomegalovirus (CMV) immunoglobulin for the prevention of CMV disease in 31 CMV-seropositive heart transplant recipients who had received early immunoprophylaxis with OKT3 monoclonal antibodies. The incidence of CMV disease and visceral involvement was much higher in the CMV immunoglobulin group than in the ganciclovir group (40 versus 6%, respectively; P = 0.03). No adverse effects were found in the CMV immunoglobulin group, but 19% of the patients in the ganciclovir group developed mild leukopenia or a mild increase in their serum creatinine levels.
Full Text
The Full Text of this article is available as a PDF (162.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balk A. H., Weimar W., Rothbarth P. H., Meeter K., Metselaar H. J., Mochtar B., Simoons M. L. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience. Infection. 1993 Jul-Aug;21(4):195–200. doi: 10.1007/BF01728886. [DOI] [PubMed] [Google Scholar]
- Eisenmann D., Knipp H., Laube H., Stegmann T. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir. Transplant Proc. 1990 Oct;22(5):2322–2323. [PubMed] [Google Scholar]
- Gleaves C. A., Smith T. F., Shuster E. A., Pearson G. R. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985 Feb;21(2):217–221. doi: 10.1128/jcm.21.2.217-221.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Glowacki L. S., Smaill F. M. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis. Clin Transplant. 1994 Feb;8(1):10–18. [PubMed] [Google Scholar]
- Havel M., Teufelsbauer H., Laczkovics A., Kurz R., Wolner E. Cytomegalovirus hyperimmunoglobulin prophylaxis in the prevention of cytomegalovirus infection in immunosuppressed heart transplant patients. Transplant Proc. 1990 Aug;22(4):1805–1806. [PubMed] [Google Scholar]
- Hibberd P. L., Tolkoff-Rubin N. E., Cosimi A. B., Schooley R. T., Isaacson D., Doran M., Delvecchio A., Delmonico F. L., Auchincloss H., Jr, Rubin R. H. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992 Jan;53(1):68–72. doi: 10.1097/00007890-199201000-00013. [DOI] [PubMed] [Google Scholar]
- Lumbreras C., Otero J. R., Herrero J. A., Gomez R., Lizasoain M., Aguado J. M., Colina F., Garcia I., Moreno E., Noriega A. R. Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother. 1993 Nov;37(11):2490–2492. doi: 10.1128/aac.37.11.2490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Merigan T. C., Renlund D. G., Keay S., Bristow M. R., Starnes V., O'Connell J. B., Resta S., Dunn D., Gamberg P., Ratkovec R. M. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992 Apr 30;326(18):1182–1186. doi: 10.1056/NEJM199204303261803. [DOI] [PubMed] [Google Scholar]
- Snydman D. R., Werner B. G., Dougherty N. N., Griffith J., Rubin R. H., Dienstag J. L., Rohrer R. H., Freeman R., Jenkins R., Lewis W. D. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993 Nov 15;119(10):984–991. doi: 10.7326/0003-4819-119-10-199311150-00004. [DOI] [PubMed] [Google Scholar]